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The emergence of resistance to antiretroviral drugs is a major obstacle to the successful treatment of human
immunodeficiency virus type 1 (HIV-1)-infected patients. In this work, we correlate clinical and virological
trends such as viral load (VL) and CD4 counts to genotypic and phenotypic antiretroviral (ARV) resistance
profiles of HIV-1 isolates from the B and non-B subtypes found in vertically infected children failing ARV
therapy. Plasma samples were collected from 52 vertically HIV-1-infected children failing different ARV
therapies. Samples underwent HIV-1 pol sequencing and phenotyping and were clustered into subtypes by
phylogenetic analysis. Clinical data from each patient were analyzed together with the resistance (genotypic
and phenotypic) data obtained. Thirty-five samples were from subtype B, 10 samples were non-B (subtypes A,
C, and F), and 7 were mosaic samples. There was no significant difference concerning treatment data between
B and non-B clades. Prevalence of known drug resistance mutations revealed slightly significant differences
among B and non-B subtypes: L10I, 21 and 64%, K20R, 13 and 43%, M36I, 34 and 100%, L63P, 76 and 36%,
A71V/T, 24 and 0%, and V77I, 32 and 0%, respectively, in the protease (0.0001 < P < 0.0886), and D67N, 38
and 8%, K70R, 33 and 0%, R211K, 49 and 85%, and K219Q/E, 31 and 0%, respectively, in the reverse
transcriptase (0.0256< P< 0.0704). Significant differences were found only in secondary resistance mutations
and did not reflect significant phenotypic variation between clade B and non-B.
One of the major causes of treatment failure during antiret-
roviral (ARV) therapy is the emergence of human immuno-
deficiency virus type 1 (HIV-1) genotypic variants carrying
viral protease and reverse transcriptase (RT) mutations con-
ferring resistance to antiretroviral compounds (8). These vari-
ants have been studied, and their resistance-conferring substi-
tutions were mapped in the viral pol gene for each ARV drug
(7, 15, 16). These substitutions can be classified into primary
and secondary mutations. Primary mutations lead to a sever-
alfold decrease in sensitivity to one or more ARV drugs (15,
16). Secondary mutations may not result in a significant de-
crease in drug sensitivity but are associated with restoration of
the original viral fitness in the presence of existing inhibitors
(15, 16). These studies have been carried out in detail for clade
B viruses, the prevalent HIV-1 subtype in the United States
and western Europe, although this is not the main subtype of
HIV infections worldwide. There are few data on genotypic
resistance in non-B subtypes of HIV-1 (5, 6, 12, 17). The non-B
HIV-1 strains usually carry pol gene polymorphisms as genetic
fingerprints that can give these viruses a lower susceptibility to
the ARV compounds (5, 6, 12, 17, 29). Hence, the genetic
polymorphisms of non-B HIV-1 pol may lead to the establish-
ment of specific resistance patterns that differ slightly from
those found for B viruses, and may alter the interpretation of
genotyping assays.
The concern about the currently limited information about
known resistance patterns of non-B HIV strains can be ex-
tended to pediatric ARV treatment of AIDS. Recent studies
have reported unique virus population dynamics in vertically
infected children (17, 29), although very little is known about
the infection, disease progression, and genotypic and pheno-
typic resistance profiles in children harboring clade B drug-
resistant HIV-1 variants (9, 13, 19, 21, 25).
In Brazil, non-B virus strains can be found, such as those
from clades F (18% prevalence), C (frequently found in the
southernmost part of the country), D, and A. There are also
B/F, B/C, and B/D mosaics (20, 23, 26). The prevalence of
circulating drug-resistant strains of virus in Brazil has been
reported only for drug-naive and treated adults (3, 5, 6, 27).
The STD/AIDS Program of the Brazilian Ministry of Health
estimates that 5,426 children were infected with HIV in Brazil
up to April 2001 (2). A large proportion of them are currently
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undergoing ARV treatment. The present study is a compara-
tive analysis of clinical and virological data with its focus on
comparisons of genotypic and phenotypic viral resistance pat-
terns between different clades (B and non-B) found in HIV-
infected Brazilian infants failing antiretroviral therapy.
MATERIALS AND METHODS
Study population. Samples were obtained from HIV-1-seropositive children
attending the university hospitals in Rio de Janeiro and Sa˜o Paulo, Brazil.
Plasma samples were collected from 52 vertically HIV-infected children (2 to 14
years of age) failing different ARV therapies (19 were receiving dual-nucleoside
analog inhibitor [dual-NRTI] therapy only, and 33 were under highly active
antiretroviral treatment [HAART], 8 of whom had not received dual-NRTI
regimens before being given HAART). The criteria of failure were based on
viral-load responses, according to the treatment consensus of the AIDS program
from the Brazilian Ministry of Health (2). All samples collected during 1 year
(from April 1999 to April 2000) and successfully analyzed were included in this
study.
Sample data collection. The CD4 counts and plasma HIV RNA levels (viral
load [VL]) were routinely determined for each patient, as determined and
supported by the Brazilian Program for STD/AIDS, National Ministry of Health,
to facilitate appropriate clinical care. All information concerning each patient
(CD4 cell counts, latest and previous viral loads, detailed ARV and other treat-
ment history, and clinical classification of HIV infection progression according to
the criteria of the Centers for Disease Control and Prevention, Atlanta, Ga.) was
provided by the AIDS clinics of the two hospitals in Brazil. Most of this infor-
mation was cross-analyzed in conjunction with the genotypic and phenotypic
data.
Plasma HIV RNA levels were measured by reverse transcription-PCR (RT-
PCR) (Cobas Amplicor; Roche Diagnostics, Nutley, N.J.) or nucleic acid se-
quence-based amplification technology (Nuclisens; Organon Teknika, Boxtel,
The Netherlands).
Virus isolation and HIV-1 pol genotyping. Isolation of virus from plasma
samples and analysis of HIV-1 pol sequences were performed with the Prt/5 RT
HIV-1 genotyping system (Applied Biosystems, Foster City, Calif.). Briefly,
HIV-1 RNA was isolated from plasma and reverse transcribed with random
hexamer primers and Moloney murine leukemia virus RT. An HIV-1 DNA
fragment including the regions encoding protease (amino acids 1 to 99) and RT
(amino acids 1 to 310) was amplified by PCR using TaqGold in a single 40-cycle
reaction. The amplified DNA was then purified and sequenced with six or seven
primers and BigDye terminator reagents with an ABI model 377 automated
DNA sequencer (Applied Biosystems). Sequences were edited, aligned, trans-
lated into amino acids, and analyzed for the presence of amino acid polymor-
phisms.
Phylogenetic analysis. The genetic subtypes were determined by phylogenetic
tree analysis. The nucleotide sequences from clinical isolates and the sequences
of reference strains representing the different genetic subtypes, based on the
protease and RT genes, were aligned by the CLUSTAL multiple sequence
alignment programs (28). Phylogenetic trees were constructed by the neighbor-
joining distance method (24). Evolutionary distances were estimated using the
Kimura two-parameter method. Phylogenetic and molecular evolutionary anal-
yses were conducted using MEGA version 2.0 (18). An interior-branch test for
the nodes was also performed with MEGA version 2.0, using representative
standards belonging to different subtypes obtained from the Los Alamos Na-
tional Laboratory database. The simian immunodeficiency virus cpz sequence
was used as the outgroup.
HIV-1 pol phenotyping. The detection of HIV-1 phenotypic resistance to Food
and Drug Administration (FDA)-approved ARV compounds was performed
using a recombinant virus assay technology (Virco, Mechelen, Belgium). The
HIV-1 RNA was extracted from plasma samples, and a 2.2-kb fragment contain-
ing the entire HIV-1 pol (protease and RT) coding sequence was amplified by
nested RT-PCR. The pool of pol coding fragments was then cotransfected into
CD4 T lymphocytes (MT4) with the pGEMT3PRT plasmid carrying the
defective pol HIV genomic cDNA. Homologous recombination leads to gen-
eration of chimeric virus containing pol sequence derived from patients’ viruses.
The susceptibility of chimeric virus to all the FDA-approved antiretroviral com-
pounds was determined by an MT4 cell 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide-based cell viability assay in an automated system as
previously described (14).
Statistical analysis. All statistical treatments were performed using the Ana-
lyse-it v. 1.62 for Microsoft Excel statistics package. Statistical analysis of differ-
ences between mutation frequencies and also between phenotypic categories
(resistant and wild-type isolates) was carried out using Fisher’s two-tailed exact
test on 2  2 contingency tables, with   0.05. The sample means are always
shown together with the standard error of the mean (mean  SEM).
RESULTS
Phylogenetic analysis of samples. Among the 52 samples
successfully analyzed, there were 35 B-subtype samples and 10
non-B. Seven samples with mosaic pol structures were also
found, with four F/B and three B/F genotypes, for the protease
and RT genes, respectively (Table 1). Of the 10 non-B samples,
8 (15.4% of the total 52) clustered with clade F of HIV-1 group
M. One clade C sample and one clade A sample were also
found. All subtypes were confirmed by HIV env gp41IDR
sequencing and phylogenetic analysis (data not shown), and
mosaic B/F and F/B pol samples clustered with B or F clades
for this env region, with no specific significant correlation with
each pol mosaic arrangement. For subsequent analysis of re-
sistance mutations, each target gene for therapy (protease or
RT) was considered separately to avoid misinterpretation due
to the presence of these mosaic genotypes.
Treatment data. Three types of ARV regimens could be
observed at the time of sample collection for genotyping: 19
patients (15 infected with B viruses and 4 infected with non-B
viruses) were receiving dual-NRTI regimens with no experi-
ence of HAART, 25 patients (14 infected with B viruses, 5
infected with non-B viruses, and 6 infected with mosaic vi-
ruses) were receiving HAART with a history of dual-NRTI
regimens, and 8 patients (6 infected with B viruses 1 infected
with a non-B virus, and 1 infected with a mosaic virus) had
received only HAART (Table 2). There were no differences
between subtypes for the different regimens used, the average
duration of the most recent and previous regimens used, or the
average number of different regimens used during the clinical
history of each patient. The ARV drug usage in the regimens
was essentially the same for patients infected with the different
subtypes. Saquinavir was not used in children because no com-
pound formulation was available for pediatric use.
Clinical data for infants infected with different subtypes were
not significantly different, including age and VL (the two were
collected at the time of blood sampling for genotyping) (Table
3). Strikingly, when the CD4 counts were compared between
children infected with subtype B and non-B viruses, higher
values were found in clade B (P  0.0208; one-tailed hetero-
cedastic Student’s t test).
TABLE 1. Classification of samples according to subtypes
Subtype No. of samples Total no. per subtype
B 35 35
Non-B 10
F 8
C 1
A 1
Mosaicsa 7
B/F 3
F/B 4
a Classification of samples was based on cDNA sequence phylogeny based on
both pro and rt HIV genes.
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Resistance mutations in the protease gene. The overall fre-
quency of protease genotypes resistant to protease inhibitors
(PIs) was 44.23%, with no difference among subtype B and
non-B viruses. The most common resistant protease genotypes
were those carrying primary mutations to positions 54 and 82
(10 genotypes), 54, 82, and 90 (4 genotypes), and 30 (3 geno-
types) in the protease protein.
Frequencies of relevant resistance-associated mutations (7)
TABLE 2. Treatment data for infant HIV-1 infections with different viral subtypesa
Patient group and characteristic
Value for group
Subtype B Other subtypes(A, C, and F)
Mosaics
(B/F and F/B)
Patients receiving dual-NRTI-only regimens
No. of patients 15 4
Average duration of treatment (mo) (mean  SEM) 20  2.7 17  7
Average no. of different dual-NRTI-only regimens (mean  SEM) 1  0.13 1  0.25
Patients receiving HAART
No. of patients with previous dual-NRTI regimen(s) 14 5 6
Average duration of treatments, including different dual-NRTI regimens (mo)
(mean  SEM)
30  2.26 26  5.3 29  3.4
Average no. of treatments, including different dual-NRTI regimens (mean  SEM) 3  0.14 3  0.37 3  0.36
Average duration of HAART (mo) (mean  SEM) 16  2.3 11  2.6 14  3.8
Average no. of different HAART regimens (mean  SEM) 2  0.17 1  0.2 2  0.33
No. of patients without previous dual-NRTI regimen(s) 6 1 1
Average duration of HAART (mo) (mean  SEM) 17  1.5 8b 7b
Average no. of different HAART regimens (mean  SEM) 2  0.33 2b 1b
All patients
No. (%) of patients receiving the specified drug in the following drug category:
NRTIs
Lamivudine 97 100 100
Zidovudine 100 90 100
Stavudine 66 60 86
Didanosine 34 50 57
Zalcitabine 3 —c —
NNRTIs
Nevirapine 6 20 14
PIs
Ritonavir 40 40 71
Nelfinavir 26 40 86
Indinavir 14 10 —
Saquinavir — — —
a Other commonly used antiretroviral compounds (FDA approved) are not shown here as they were not used at any group analyzed.
b Absolute numbers without SEM, representative of only one viral sample (each).
c Antiretroviral drug not used for the group.
TABLE 3. Clinical data of infant HIV-1 infections with different viral subtypesa
Subtype(s) and variable Value
Subtype B
Age (yr) [mean  SEM (range)].....................................................................................................................................................5.69  0.57 (1–12)
CD4 cell count (cells/ml) [mean  SEM (range)]b ...................................................................................................................... 906  122 (4–2,783)
Viral load (log10 copies/ml) [mean  SEM (range)]
b ..................................................................................................................4.47  0.13 (2.9–6.5)
Non-B subtypes
Age (yr) [mean  SEM (range)].....................................................................................................................................................7.20  1.13 (3–14)
CD4 cell count (cells/ml) [mean  SEM (range)]b ...................................................................................................................... 525  142 (20–1,487)
Viral load (log10 copies/ml) [mean  SEM (range)]
b ..................................................................................................................4.57  0.18 (3.4–5.4)
Mosaic B/F or F/B subtypes
Age (yr) [mean  SEM (range)].....................................................................................................................................................5.71  1.69 (1–14)
CD4 cell count (cells/ml) [mean  SEM (range)]b ...................................................................................................................... 685  102 (285–977)
Viral load (log10 copies/ml) [mean  SEM (range)]
b ..................................................................................................................4.78  0.30 (3.9–6.2)
a HIV-1 subtypes were determined by phylogenetic analysis of pro and rt sequencing.
b Viral load and CD4 counts of patients at the time of blood sampling for genotyping.
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were compared among the subtype groups in the protease
region of viruses (Table 4). The prevalence of known drug
resistance mutations among B and non-B clades in infected
children revealed significant differences: L10I/R/V/F, 21.1 and
64.3% (P  0.0102), K20M/R, 13.2 and 42.9% (P  0.0592),
M36I, 34.2 and 100% (P 0.0001), L63P, 76.3 and 35.7% (P
0.0178), A71V/T, 23.7 and 0% (P  0.0886), and V77I, 31.6
and 0% (P  0.0262), respectively in B and non-B samples.
Although nelfinavir was commonly used in children infected
with non-B virus, this group of subtypes did not present any
D30N or N88D, in contrast to the frequencies of 7.9 and 2.6%,
respectively, found in samples from infants infected with the B
subtype who were given initial HAART with nelfinavir (Table
5). All L90M resistance mutations were found in nelfinavir-
experienced children (three for subtype B and one for the
non-B group) for whom this drug was a second-choice PI in
HAART after ritonavir. The most frequent primary resistance-
related mutations in infant samples were the substitutions at
codons 82 and 54 (with no significant difference of frequency
between clades for both mutations), as expected since most
patients receiving HAART were given ritonavir as the first-
choice PI.
Resistance mutations in the RT gene. Of 52 RT genotypes
sequenced 50 (96.15%) were resistant to NRTIs and/or non-
NRTIs (NNRTIs). The most common RT genotypes found to
be resistant to NRTIs were those carrying primary mutations at
positions 184 (16 genotypes), 184 and 215 (16 genotypes), 70
and 184 (5 genotypes), and 70, 184, and 215 (4 genotypes) in
the RT. The most common RT genotypes resistant to NNRTIs
had primary substitutions at positions 181 (3 genotypes), 103
and 181 (2 genotypes), and 106 and 181 (2 genotypes) in the
RT.
The frequencies of resistance mutations were also assessed
for the RT region in isolates from infant patients (Table 4). All
significant differences in the mutation profiles of B and non-B
clades were related to resistance to zidovudine: D67N (38.5
and 7.7%; P  0.0704), K70R (33.3 and 0%; P  0.0256),
R211K (48.7 and 84.6%; P  0.0461) and K219Q/E (30.8 and
0%; P  0.0371); three of these (D67N, K70R, and K219Q/E)
were more frequent in the B clade. Although 100% of patients
in the B group and 90% of patients in the non-B group were
receiving zidovudine, only 46.2 and 53.8% of their samples,
respectively, presented the zidovudine primary resistance mu-
tation, T215Y/F. Inversely, the prevalence of the resistance
mutation M184V to lamivudine was equally high for both
groups of clades (86 and 90%).
Phenotyping of viral isolates. Genotypic results were con-
firmed by a phenotyping assay for the non-B samples analyzed
in this study. Fifteen samples belonging to clade B were taken
randomly, along with all non-B samples and mosaics, for the
Antivirogram phenotyping assay (Table 6). Again, the results
were analyzed separately for each target gene for therapy (pro-
tease or RT) to avoid misinterpretation due to the presence of
mosaic genotypes. No phenotypic difference could be observed
between isolates from groups B and non-B. Instead, the fold
increase of mean 50% inhibitory concentrations (IC50) ob-
tained for each drug to which the isolates were resistant was in
accordance with the genotypic prediction of resistance, based
TABLE 4. Frequency of resistance conferring mutations in the protease and RT genes
Gene and
mutation
No. (%) of mutationsa
Pc Gene andmutation
No. (%) of mutationsa
PSubtype B
(n  38)b
Non-B subtypes
(n  14)
Subtype B
(n  39)
Non-B subtypes
(n  13)
Protease gene RT gene
L10I/R/V/F 8 (21.1) 9 (64.3) 0.0102 M41L 15 (38.5) 5 (38.5) 0.7420
K20M/R 5 (13.2) 6 (42.9) 0.0592 E44D 2 (5.1) 2 (15.4) 0.5147
L24I 2 (5.3) 1 (7.1) NSd K65R 1 (2.6) NS
D30N 3 (7.9) 0.7634 D67N 15 (38.5) 1 (7.7) 0.0704
M36I 13 (34.2) 14 (100.0) 0.0001 T69D/N 1 (2.6) NS
M46I/L 3 (7.9) 1 (7.1) NS K70R 13 (33.3) 0.0256
I47V/T 1 (2.6) NS V75I/L 1 (2.6) NS
G48V F77L 1 (2.6) NS
I50V/L K103N 4 (10.3) 0.6076
I54V/L 11 (28.9) 6 (42.9) 0.5320 V106A/I 2 (5.1) 1 (7.7) NS
L63P 29 (76.3) 5 (35.7) 0.0178 Y115F 1 (2.6) NS
A71V/T 9 (23.7) 0.0886 F116Y 1 (2.6) NS
G73S V118I 3 (7.7) 1 (7.7) NS
V77I 12 (31.6) 0.0262 Q151M 1 (2.6) NS
V82A/F/T/S 11 (28.9) 5 (35.7) 0.8807 Y181C/I 6 (15.4) 1 (7.7) 0.8640
I84V M184V/I 33 (84.6) 11 (84.6) NS
N88D 1 (2.6) NS G190A 1 (2.6) NS
L90M 3 (7.9) 1 (7.1) NS L210W 8 (20.5) 1 (7.7) 0.5500
R211K 19 (48.7) 11 (84.6) 0.0461
L214F 8 (20.5) 1 (7.7) 0.5500
T215F/Y 18 (46.2) 7 (53.8) 0.8716
K219Q/E 12 (30.8) 0.0379
P236L 1 (2.6) 1 (7.7) 0.8824
a Numbers of mutations found are showed first, followed by the frequencies in parentheses.
b n refers to the number of samples with this subtype for the specific gene indicated, avoiding misinterpretations due to the presence of mosaic genomes in the pol
region.
c Fisher’s exact P value, two tailed; confidence interval  95%.
d NS, not significantly different (  0.05; P  1.0000).
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TABLE 5. Genotypic profiles of viral isolates for each patient
Sample
ID
Clinical stage
of patient
(CDC)
Subtype
(protease/RT) Drugs used in therapy
a Protease resistance mutation(s)b RT resistance mutation(s)b
TVGG01 C1 B/B RTV, AZT, 3TC, DDI K20R, L24I, M36I, I54V, L63P,
V82L
M41L, D67N, K70R, M184V, T215F, K219E
TVGG02 B2 B/B AZT, 3TC, DDI L63P M41L, M184V, L210W, R211K, T215Y
TVGG04 A2 B/B INV, AZT, 3TC, D4T L10I, I54V, L63P, V77I, V82A D67N, K70R, M184V, R211K, K219Q
TVGG05 B1 B/B INV, AZT, 3TC, DDI, D4T L24I, M46L, I54V, L63P, V77I,
V82A
M41L, M184V, L210W, R211K, T215V
TVGG08 B3 B/B AZT, 3TC, D4T, DDI L63P K65R, K70R, V75I, F77L, Y115F, F116Y,
Q151M, R211K, K219E
TVGG11 C1 B/B AZT, 3TC, D4T M36I, L63P D67N, K70R, T215I, K219Q
TVGG14 B1 B/B AZT, 3TC M36I, L63P M41L, M184V, R211K, T215Y
TVGG15 B1 B/B AZT, 3TC, D4T, DDI, NVP V77I M41L, K103N, M184V, L210W, R211K,
T215F
TVGG19 A2 B/B AZT, 3TC, D4T L10V, L63P M184V, R211K
TVGG20 A2 B/B AZT, 3TC I47T, L63P, V77I M184V, R211S
TVGG22 B1 B/B AZT, 3TC L63P, V77I M184V
TVGG23 B3 B/B AZT, DDC L10V, L63P, V77I D67N, K70R, M184V, T215F, K219Q
TVGG24 B1 B/B AZT, 3TC L63P, V77I D67N, K70R, M184V, R211K, K219Q
TVGG25 B3 B/B INV, AZT, 3TC, DDI L63P, A71T M41L, M184V, R211K, T215F
TVGG28 C3 B/B INV, RTV, AZT, 3TC, D4T M36I, I54V, L63P, V28M, L90M D67N, K70R, M184V, F214L, T215F,
K219E, P236L
TVGG30 B1 B/B RTV, NFV, 3TC, D4T, AZT L63P, A71V, V82A, I54V, L90M M41L, E44D, V118I, M184V, L210W,
T215Y
TVGG33 B2 B/B AZT, 3TC, D4T, DDI L63P, V77I M41L, D67N, K103N, Y181C, M184V,
L210W, R211K, T215Y
TVGG34 B1 B/B AZT, 3TC, D4T, DDI L10V
TVGG35 B3 B/B AZT, 3TC, D4T L63P M41L, D67N, V118I, M184V, L210W,
R211K, T215V
TVGG37 B1 B/B AZT, 3TC L63P, V77I D67N, K70R, M184V, F214L, K219Q
TVGG38 C3 B/B INV, RTV, NFV, AZT, 3TC,
D4T, DDI
L10F, M46L, I54V, L63P, V82A M41L, E44D, D67N, V75M, K103N,
V118I, Y181I, M184V, L210W, R211K,
T215Y, K219N
TVGG39 C2 B/B AZT, 3TC, DDI K70R, M184V
TVGG42 N1 B/B AZT, 3TC L63P M41L, M184V, T215F
TVSP02 B3 B/B RTV, NVP, NFV, AZT, 3TC,
D4T
L10I, K20R, M36I, I54V, L63P,
A71V, V82A
V106A, Y181C, R211K, F214L
TVSP03 B2 B/B RTV, D4T, AZT, 3TC V82A Y181C, M184V, F214L
TVSP05 A2 B/B RTV, D4T, AZT, 3TC K20R, M36I, I54V, L63P, A71V,
V82A
G190A, R211K
TVSP06 B1 B/B RTV, NFV, D4T, AZT, 3TC L10V, K20R, M36I, I54V,
A71V, V82A
M184V
TVSP07 C3 B/B RTV, NFV, D4T, 3TC, AZT D30N, M36I, L63P, A71V,
N88D
M41L, D67N, M184V, L210W, R211K,
T215Y
TVSP10 A3 B/B RTV, D4T, DDI, 3TC, AZT V77I M184V, T215Y
TVSP11 C2 B/B NFV, D4T, 3TC, AZT D30N, L63P, A71V, V77I Y181C, M184V, R211A, T215Y
TVSP12 N1 B/B RTV, AZT, 3TC M36I M184V, R211K, F214L
TVSP14 A1 B/B RTV, NFV, DDI, D4T, AZT, 3TC L63P, V82A M184V
TVSP16 A1 B/B RTV, AZT, 3TC, D4T, DDI L10V, K20R, M36I, I54V, V82A D67N, K70R, M184V, R211K, F214L,
K219Q
TVSP17 B1 B/B RTV, NFV, 3TC, D4T, AZT I54V, L63P, A71V, V82A, L90M M184V
TVSP19 C3 B/B NFV, AZT, 3TC, D4T D30N, M36I, L63P M41L, V106I, M184V, F214L, T215F
TVSP04 A3 B/F NFV, AZT, DDI, 3TC, D4T M36I, M46I, L63P, A71T M184V, R211K
TVSP09 C2 B/F RTV, NFV, 3TC, AZT M36I R211K
TVSP24 C2 B/F RTV, NFV, AZT, DDI, 3TC,
D4T
L63P, V77I M184V, R211K, T215F
TVGG03 B2 F/B NFV, AZT, 3TC, DDI, D4T L10V, M36I, I54V, L63P, V82A D67N, T69D, K70R, M184V, T215F, K219Q
TVGG12 C2 F/B NFV, RTV, AZT, 3TC, D4T,
NVP
L10I, K20R, M36I, M46I, I54V,
V82A
M41L, D67N, K70R, Y181C, T215Y, K219E
TVSP15 C3 F/B RTV, NFV, 3TC, D4T, AZT L10I, L24I, M36I, V82L M41L, D67N, K70R, M184V, R211K,
T215F, K219E
TVSP18 C3 F/B RTV, AZT, DDI, 3TC, D4T L10I, K20R, M36I, I54V, L63P M184V, R211K, F214L
TVGG13 B1 F/F AZT, 3TC M36I, L63S M41L, M184V, R211Q, T215Y
TVGG17 B1 F/F AZT, 3TC, DDI L10V, K20R, M36I M184V, R211K
TVGG18 C2 F/F AZT, 3TC L10I, M36I, L63T M41L, M184V, R211K, T215F
TVGG21 B3 F/F RTV, AZT, 3TC, DDI, D4T L10I, K20R, M36I, L63P, I54V,
V82A
V118I, M184V, R211K, F214L, T215F
TVGG27 C3 F/F RTV, NFV, 3TC, D4T, DDI, NVP L10I, K20R, M36I, I54V, V82A,
L90M
M41L, E44D, D67N, K70S, V106A, Y181C,
R211K, T215Y
TVSP01 B2 F/F RTV, NFV, 3TC, D4T, AZT K20R, M36I, I54V, L63P, V82A M41L, E44D, M184V, R211K, T215F
TVSP21 A3 F/F RTV, INV, NFV, 3TC, D4T,
AZT, DDI
M36I M184V
TVSP22 C3 F/F RTV, INV, NFV, AZT, DDI,
3TC, D4T
M36I M184V, R211K
TVGG07 B3 A/A AZT, 3TC, D4T, NVP L10I, M36I, L63V, M41L, M184V, L210W, R211K, T215F
TVGG41 A2 C/C AZT, 3TC M36I, L63P M184V, R211K, P236L
a Drug abbreviations: AZT, zidovudine; 3TC, amivudine; DDI, didanosine; DDC, zalcitabine; D4T, stavudine; ABC, abacavir; NVP, hevirapine; DLV, delavirdine;
EFV, efavirenz; SQV, saquinavir; INV, indinavir; RTV, ritonavir; NFV, nelfinavir; APV, amprenavir. The last therapy regimen included the drugs listed in boldface,
italic type.
b The amino acid substitutions were classified as primary or secondary resistance mutations based on reference 7. Primary resistance mutations are listed in boldface,
italic type, while secondary resistance mutations are listed in roman type.
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on each isolate genotypic profile and the published guides to
interpretation of genotyping (7).
Three samples showed primary resistance mutations to
NNRTI (K103N and Y181I for TVGG38, Y181C for TVSP11,
and V106A for TVSP19), without any history of previous pa-
tient exposure to this class of inhibitors. These mutations
found in virus isolates were able to confer in vitro resistance to
NNRTIs as revealed by the phenotypic assay.
DISCUSSION
In this study, clinical and treatment data for infected chil-
dren were homogeneous across clades, except that the CD4
cell counts were higher in patients infected with B virus than in
those infected with non-B virus.
We were able to find a strong correlation between the ther-
apeutic failure in children receiving ARV and the presence of
primary resistance mutations in the pol genotypes of their virus
isolates. Of 52 pol genotypes analyzed, 50 (96.15%) carried
primary mutations conferring resistance to at least one class of
antiretroviral drug among those used in therapy for each pa-
tient analyzed. In detail, we found a higher frequency of RT
genes carrying primary mutations (96.15%) than protease
genes with this kind of substitution (44.23%). No difference
was found in the frequency of these mutations between B and
non-B subtype isolates. Only two isolates did not present any
primary mutation to ARV resistance (TVGG34 and TVSP09);
this is probably related to patient nonadherence to the therapy.
From the genotypic analysis of the protease region, we could
detect subtype differences only among secondary resistance
mutations, such as in residues 10, 20, 36, 63, 71, and 77. The
variation found in the frequency of these mutations is probably
a consequence of the natural occurrence of polymorphisms as
genetic fingerprints in non-B isolates. Although there is no
evidence of direct correlation between the variation in second-
ary resistance substitutions present in different clades and their
phenotypic resistance profiles (5, 7), we speculate that these
non-B genetic variations play an important role in augmenting
the viral fitness of isolates carrying primary resistance muta-
tions. Such differences lead to alternative paths to resistance
TABLE 6. Phenotypic profiles (Antivirogram) of samples from different subtypes
Sample
ID
Subtype
(protease/
RT)
Drugs used in
therapyb
IC50 increase fora:
NRTIs NNRTIs PIs
AZT 3TC ddI ddC D4T ABC NVP DLV EFV INV RTV NFV SQV APV LPV
TVGG04 B/B INV, AZT, 3TC, D4T 	35.8 3.2 5.2 4.1 8.7
TVGG11 B/B AZT, 3TC, D4T
TVGG14 B/B AZT, 3TC 	35.8
TVGG24 B/B AZT, 3TC 	23.4 3.4
TVGG30 B/B RTV, NFV, 3TC, D4T, AZT 14.6 	23.4 9.7 40.6 100.3 23.8 4.5 16.2
TVGG38 B/B INV, RTV, NFV, AZT, 3TC,
D4T, DDI
	35.8 	36.9 	186.7 5.2 12.6 5.3 14.7
TVGG42 B/B AZT, 3TC 	35.8
TVSP02 B/B RTV, NVP, NFV, AZT, 3TC,
D4T
	36.9 25.3 19.0 4.1 7.6
TVSP06 B/B RTV, NFV, D4T, AZT, 3TC 	23.4 5.7 17.7 5.8 10.4
TVSP07 B/B RTV, NFV, D4T, 3TC, AZT 	20.5 4.5 16.0
TVSP11 B/B NFV, D4T, 3TC, AZT 	23.4 4.6 5.8 	45.6 13.8 11.3
TVSP17 B/B RTV, NFV, 3TC, D4T, AZT 	23.4 15.7 4.6
TVSP19 B/B NFV, AZT, 3TC, D4T 	23.4 24.9 18.5
TVSP12 B/B RTV, AZT, 3TC 	35.8 5.4
TVSP16 B/B RTV, AZT, 3TC, D4T, DDI 	35.8 16.9 4.5
TVSP04 B/F NFV, AZT, DDI, 3TC, D4T 	35.8
TVSP09 B/F RTV, NFV, 3TC, AZT
TVSP24 B/F RTV, NFV, DDI, AZT, DDI,
3TC, D4T
5.3 	23.4
TVSP15 F/B RTV, NFV, 3TC, D4T, AZT 14.1 	23.4 6.0 23.7 5.3
TVGG03 F/B NFV, AZT, 3TC, DDI, D4T 	23.4
TVGG12 F/B NFV, RTV, AZT, 3TC, D4T,
NVP
8.2 	45.6 	157.7 7.4 59.6 16.3 20.7
TVGG13 F/F AZT, 3TC 	35.8
TVGG17 F/F AZT, 3TC, DDI 	35.8
TVGG18 F/F AZT, 3TC 	35.8
TVGG21 F/F RTV, AZT, 3TC, DDI, D4T 	35.8 14.7
TVGG27 F/F RTV, NFV, 3TC, D4T, DDI,
NVP
6.3 5.6 	36.9 9.3 6.8 43.6 10.8
TVSP01 F/F RTV, NFV, 3TC, AZT, D4T 	35.8 11.9
TVSP21 F/F NFV, 3TC, D4T, AZT, DDI 	23.4
TVSP22 F/F RTV, INV, NFV, AZT, DDI,
3TC, D4T
	23.4
TVGG07 A/A AZT, 3TC, D4T, NVP 4.7 	35.8
TVGG41 C/C AZT, 3TC 	23.4
a The numbers represent the fold increase of mean IC50 s of these drugs for viral samples compared to the mean IC50 for untreated or wild-type viruses. Only values
representing significant levels of resistance to each drug (high resistance) are shown, to clarify data presentation.
b Drug abbreviations are as indicated in footnote a of Table 5.
VOL. 40, 2002 DRUG RESISTANCE OF HIV-1 CLADES B AND NON-B IN INFANTS 4517
through the genetic barrier for non-B clades and may influence
the progression to resistance during drug therapy of infant
HIV-1 infection. These findings are in accordance with the
analyzed data reported in a recent study that compared the
genotypic variation between the prevalent clades, B and C, in
Israel (12), as well as in other studies reporting genotypic
differences between clades only in the secondary resistance
mutation patterns (4, 6, 10, 11, 12, 17, 27). A high frequency of
ritonavir and nelfinavir resistance mutations was detected, in
contrast to the low prevalence found by others in infants (9).
The RT gene mutation patterns between B and non-B sub-
types were basically the same and varied only in residues re-
lated to zidovudine resistance, which occurred more frequently
in B subtype isolates (except for R211K), as observed else-
where (12). The primary substitution T215Y/F was found fre-
quently in both B and non-B clades, and the difference in the
zidovudine resistance genetic profile occurred mostly in other
residues involved in conferring zidovudine resistance (RT res-
idues 67, 70, 211, and 219). This may suggest that different
mechanisms were used among clades to achieve the increased
pyrophosphorolysis activity and processivity seen in RT en-
zymes highly resistant to AZT (1).
In some infants, we found viruses harboring mutations con-
ferring resistance to NNRTIs, although some of the infants
were not exposed to this class of drugs, as observed by others
(12). This may be related to the capacity of viruses to carry
these mutations without changing their RT activity. These re-
sults confirm the usefulness of the genotypic test for guiding
the rescue therapy of pediatric AIDS patients failing HAART
in Brazil.
There was no evidence from our results of different patterns
of genotypic and phenotypic resistance to ARV compounds of
viral isolates from children failing ARV therapy in comparison
with the widely studied patterns of isolates from adults (7, 12,
17, 21, 27).
We suggest that HIV-1 protease and RT variability among
different clades might influence the efficacy of ARV treat-
ments. These results call for careful investigations implement-
ing well-controlled genotyping and phenotyping clinical trials
with follow-up of patients infected with non-B subtype virus
before starting large therapy programs in countries where the
majority of the HIV-1 epidemic is driven by non-B-subtype
strains.
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